|Articles|April 10, 2009

WOTY-Podcast:Maureen Regan

Maureen Regan

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Robert Allen, Ph.D., Chief Scientific Officer

Staying Ahead of Viral Evolution: Q&A with Robert Allen, Ph.D

ByNicholas Jacobus,Robert Allen, Ph.D.,

July 20th 2026

How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?

ByNicholas Jacobus,Gerren McHam

July 20th 2026

Hiring and Fostering Top Talent

ByMike Hollan,David Hung

July 20th 2026

Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta

ByNicholas Jacobus

July 17th 2026

FDA Approves Fabhalta to Slow Kidney Function Decline in Primary IgAN in Adults

ByNicholas Jacobus

July 17th 2026

WOTY-Podcast:Maureen Regan

Related Content

Staying Ahead of Viral Evolution: Q&A with Robert Allen, Ph.D

How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?

Hiring and Fostering Top Talent

Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta

FDA Approves Fabhalta to Slow Kidney Function Decline in Primary IgAN in Adults

Trending on PharmExec

Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement

Staying Ahead of Viral Evolution: Q&A with Robert Allen, Ph.D

FDA Approves Lipfendra to reduce LDL-C in Adults with Hypercholesterolemia

How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?

Eli Lilly to Acquire AtaiBeckley for $2.8 Billion